Effect of Acorus calamus L. Polysaccharide on CD274 and CD326 Expression by Lewis Lung Carcinoma Cells in Mice


Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Только для подписчиков

Аннотация

Tumor cells can maintain their growth via immunosuppression and escape from host antitumor immunity by controlling the PD-1/PD-L1 system. Expression of PD-L1 (CD274) is an inhibitory signal for T cells, while the increase in CD326 expression in the tumor tissue correlates with metastasis development. The experimental preparation on the basis of α(1,2)-L-rhamno-α(1,4)-D-galactopyranosyluronan from Acorus calamus L. produces an antitumor effect: it reduces tumor node size and the number and area of metastases after transplantation of Lewis lung carcinoma. Using flow cytometry, we demonstrated a decrease in the population of tumor cells expressing surface CD274 (PD-L1) and CD326 antigens after 20-day course of α(1,2)-L-rhamno-α(1,4)-D-galactopyranosyluronan.

Об авторах

K. Lopatina

Laboratory of Oncopharmacology, E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center; Laboratory of Phytochemistry of Siberian Botanical Garden of National Research Tomsk State University

Автор, ответственный за переписку.
Email: k.lopatina@pharmso.ru
Россия, Tomsk; Tomsk

E. Safonova

Laboratory of Oncopharmacology, E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center

Email: k.lopatina@pharmso.ru
Россия, Tomsk

K. Nevskaya

Department of Pharmaceutical Analysis, Centre for Introduction of Technologies, Siberian State Medical University, Ministry of Health of the Russian Federation

Email: k.lopatina@pharmso.ru
Россия, Tomsk

M. Stakheeva

Laboratory of Molecular Oncology and Immunology, Research Institute of Oncology, Tomsk National Research Medical Center

Email: k.lopatina@pharmso.ru
Россия, Tomsk

A. Gur’ev

Department of Pharmaceutical Analysis, Centre for Introduction of Technologies, Siberian State Medical University, Ministry of Health of the Russian Federation

Email: k.lopatina@pharmso.ru
Россия, Tomsk

E. Zueva

Laboratory of Oncopharmacology, E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center

Email: k.lopatina@pharmso.ru
Россия, Tomsk

T. Razina

Laboratory of Oncopharmacology, E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center

Email: k.lopatina@pharmso.ru
Россия, Tomsk

E. Amosova

Laboratory of Oncopharmacology, E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center

Email: k.lopatina@pharmso.ru
Россия, Tomsk

S. Krylov

Laboratory of Oncopharmacology, E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center

Email: k.lopatina@pharmso.ru
Россия, Tomsk

M. Belousov

Department of Pharmaceutical Analysis, Centre for Introduction of Technologies, Siberian State Medical University, Ministry of Health of the Russian Federation

Email: k.lopatina@pharmso.ru
Россия, Tomsk


© Springer Science+Business Media, LLC, part of Springer Nature, 2017

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах